This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.


As a leading provider of cancer screening and genomic-based diagnostic tests, we are relentless in our pursuit to find the right science and technology for every challenge. Our approach is defined not only by our rigorous process, but also by our willingness to explore any angle that leads to the best answer. We combine resourcefulness, expertise, and an open mind to develop life-changing innovations, rooted in the needs of patients, clinicians, and families.

Precision Oncology

The Oncotype IQ® portfolio of genomic tests are aimed at helping individual cancer patients and their clinicians uncover underlying cancer biology to guide treatment decisions and help to avoid over- and undertreatment.



Our leading screening brand, Cologuard®, is the first and only FDA-approved stool DNA test for colorectal cancer and is included in the American Cancer Society’s colon cancer screening guidelines. The Cologuard test is available only in the United States.

The Pipeline

Through our pipeline efforts, we want to change the way cancer is diagnosed and treated by finding it earlier and providing better information to patients and clinicians at every step of the cancer journey.


You are now leaving this site.

Any third-party link you select from this site may take you to an Exact Sciences website intended for US audiences or a website that is not affiliated with Exact Sciences.